

Author Correction: CAR immune cells: design principles, resistance and the next generation

<https://doi.org/10.1038/s41586-023-06088-3>

Published online: 20 June 2023

Correction to: *Nature* <https://doi.org/10.1038/s41586-023-05707-3>

Published online 22 February 2023

 Check for updates

Louai Labanieh & Crystal L. Mackall

In the version of this article initially published, the Fig. 1 timeline was missing an entry for 2009: “CD19.BB.z-CAR shows enhanced anti-leukemic efficacy and prolonged survival in mouse xenograft models of primary human B-ALL (Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Mol. Ther.* **17**, 1453–1464 (2009))”. In Box 1, the “Cytokines: IL-18” entry was missing two references : Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. *Cell Rep.* **20**, 3025–3033 (2017) and Svoboda, J. et al. Interleukin-18 secreting autologous anti-CD19 CAR T-cells (huCART19-IL18) in patients with non-Hodgkin lymphomas relapsed or refractory to prior CAR T-cell therapy. *Blood* **140**, 4612–4614 (2022). The errors have been corrected in the HTML and PDF versions of the article.

© Springer Nature Limited 2023